Cochrane · systematic review · CD012161
Short‐acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus
Fullerton, B, Siebenhofer, A, Jeitler, K, et al. · Cochrane Database of Systematic Reviews · 2016 · Cochrane Library
Metabolic and Endocrine DisordersAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
2
No studies
5
Included studies
NR
No studies 5 · 71.4%Ungraded 0 · 0%Very low 1 · 14.3%Low 1 · 14.3%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Short‐acting insulin analogues compared with regular human insulin for adults with type 1 diabetes mellitus
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality Short‐acting insulin analogues vs regular human insulin | no estimate extracted | NR | No studies |
Macrovascular complications Short‐acting insulin analogues vs regular human insulin | no estimate extracted | NR | No studies |
Microvascular complications Short‐acting insulin analogues vs regular human insulin | no estimate extracted | NR | No studies |
Severe hypoglycaemic episodes (heterogeneous definitions of severe hypoglycaemia) Short‐acting insulin analogues vs regular human insulin | OR 0.89 [0.71, 1.12] | 7 studies · 2459 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Health‐related quality of life Short‐acting insulin analogues vs regular human insulin | no estimate extracted | NR | No studies |
HbA1c at end of Short‐acting insulin analogues vs regular human insulin | no estimate extracted | 9 studies · 2608 participants | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Costs Short‐acting insulin analogues vs regular human insulin | no estimate extracted | NR | No studies |